Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fyarro in pediatric recurrent or refractory solid tumors
NCT02975882Phase 1Completed
- Sponsor
- Children's Oncology Group
- Start
- Aug 2017
- Primary completion
- Mar 2022
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of nab-sirolimus in Not applicable, solid tumor, central nervous system tumor and 1 more, sponsored by Children's Oncology Group. Started Aug 2017; status: completed.
02
Drugs
nab-sirolimus
03
Conditions
Not applicablesolid tumorcentral nervous system tumorrefractory central nervous system tumor
Beyond the preview
Go deeper on NCT02975882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02975882.